Distinguished in Waldenstrom Macroglobulinemia

Ramon G. Sanz

Salamanca, CL, ES 
Distinguished in Waldenstrom Macroglobulinemia
Salamanca, CL, ES 
OverviewLocationsClinical Research

Overview

Ramon Sanz practices in Salamanca, Spain. Mr. Sanz is rated as a Distinguished expert by MediFind in the treatment of Waldenstrom Macroglobulinemia. His top areas of expertise are Waldenstrom Macroglobulinemia, Hodgkin Lymphoma, Multiple Myeloma, and Acute Promyelocytic Leukemia.

His clinical research consists of co-authoring 13 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles and participated in 1 clinical trial in the study of Waldenstrom Macroglobulinemia.

Gender
Male

Locations

Salamanca, CL, Spain
Other Locations
Madrid, MD, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drugs: BGB-3111 (Zanubrutinib), Ibrutinib
Study Phase: Phase 3
A Randomized Multicenter Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
A Randomized Multicenter Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: November 21, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

13 Total Publications

Management of late toxicities and specific follow-up needs of adolescent and young adult cancer survivors: recommendations from scientific societies in Spain.
Management of late toxicities and specific follow-up needs of adolescent and young adult cancer survivors: recommendations from scientific societies in Spain.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: August 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Sanz's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile